ChartMill · Nov 12, 2026
Alnylam Pharmaceuticals (NASDAQ:ALNY) Emerges as a Decent Value Stock
Alnylam (ALNY) screens as decent value with a low P/E, strong margins, and robust growth, though biotech and dilution risks remain for value investors.
NYSE · ALNY
Healthcare · Biotechnology
$149.40
Down-$1.58 (-1.06%)
Updated Nov 20, 2026, 1:16 AM
SID Score
4.6/10
Composite research score
Smart Money
47/100
Neutral
Price performance · ALNY
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
ALNY closed at $149.40 after 20 trading sessions, down 34.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $155.00 | $157.28 | $147.58 | $149.40 | 2.52M |
| Nov 17, 2026 | $159.02 | $160.6371 | $155.79 | $156.50 | 2.05M |
| Nov 16, 2026 | $166.975 | $167.545 | $158.68 | $159.73 | 2.16M |
| Nov 13, 2026 | $159.17 | $168.35 | $158.825 | $165.04 | 3.59M |
| Nov 12, 2026 | $160.16 | $162.77 | $156.59 | $156.65 | 3.52M |
| Nov 11, 2026 | $152.22 | $159.92 | $151.85 | $159.85 | 3.36M |
| Nov 10, 2026 | $155.02 | $158.82 | $149.1801 | $151.64 | 2.46M |
| Nov 9, 2026 | $156.13 | $158.6975 | $152.1705 | $156.61 | 3.3M |
| Nov 6, 2026 | $155.22 | $159.45 | $154.30 | $155.94 | 2.83M |
| Nov 5, 2026 | $167.12 | $168.50 | $156.37 | $156.66 | 3.31M |
| Nov 4, 2026 | $166.73 | $170.4851 | $160.2901 | $161.08 | 3.64M |
| Nov 3, 2026 | $158.94 | $161.58 | $156.72 | $159.89 | 3.79M |
| Nov 2, 2026 | $163.10 | $163.90 | $156.0001 | $158.00 | 4.76M |
| Oct 30, 2026 | $172.695 | $180.6118 | $163.30 | $165.00 | 7.06M |
| Oct 29, 2026 | $185.59 | $202.37 | $172.31 | $174.00 | 11.8M |
| Oct 28, 2026 | $222.72 | $232.88 | $220.00 | $232.40 | 1.94M |
| Oct 27, 2026 | $225.00 | $228.49 | $222.82 | $226.79 | 1.6M |
| Oct 26, 2026 | $226.24 | $232.48 | $224.1001 | $227.66 | 1.44M |
| Oct 23, 2026 | $227.28 | $229.39 | $222.00 | $224.03 | 1.06M |
| Oct 22, 2026 | $224.92 | $229.82 | $223.76 | $227.28 | 2.21M |
The latest Smart Investors Daily articles mentioning ALNY.
Company
Market Activity
Research & News
ALNY research
Company profile and research snapshot.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 17, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 17, 2026 | Cantor Fitzgerald | Neutral | — |
| Nov 2, 2026 | Barclays | Overweight | — |
| Nov 2, 2026 | Truist Securities | Hold | — |
| Nov 2, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
ChartMill · Nov 12, 2026
Alnylam (ALNY) screens as decent value with a low P/E, strong margins, and robust growth, though biotech and dilution risks remain for value investors.
Yahoo · Nov 10, 2026
CAMBRIDGE, Mass., November 10, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that we
Benzinga · Nov 10, 2026
Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeksData shared in oral presentation at AASLD The Liver Meeting® and
Yahoo · Nov 9, 2026
CAMBRIDGE, Mass., November 09, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension (OLE) period, show that patients with transthyretin amyloidosis with cardiomyo
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ALNY.